» Articles » PMID: 35774001

A Framework for Descriptive Epidemiology

Overview
Journal Am J Epidemiol
Specialty Public Health
Date 2022 Jul 1
PMID 35774001
Authors
Affiliations
Soon will be listed here.
Abstract

In this paper, we propose a framework for thinking through the design and conduct of descriptive epidemiologic studies. A well-defined descriptive question aims to quantify and characterize some feature of the health of a population and must clearly state: 1) the target population, characterized by person and place, and anchored in time; 2) the outcome, event, or health state or characteristic; and 3) the measure of occurrence that will be used to summarize the outcome (e.g., incidence, prevalence, average time to event, etc.). Additionally, 4) any auxiliary variables will be prespecified and their roles as stratification factors (to characterize the outcome distribution) or nuisance variables (to be standardized over) will be stated. We illustrate application of this framework to describe the prevalence of viral suppression on December 31, 2019, among people living with human immunodeficiency virus (HIV) who had been linked to HIV care in the United States. Application of this framework highlights biases that may arise from missing data, especially 1) differences between the target population and the analytical sample; 2) measurement error; 3) competing events, late entries, loss to follow-up, and inappropriate interpretation of the chosen measure of outcome occurrence; and 4) inappropriate adjustment.

Citing Articles

Unmet needs among long-term breast cancer survivors.

Yarosh R, Nichols H, Hirschey R, Kent E, Mayer D, Troester M Cancer Causes Control. 2025; .

PMID: 40055257 DOI: 10.1007/s10552-025-01984-7.


Global Epidemiology of Early-Onset Aortic Aneurysm: Temporal Trends, Risk Factors, and Future Burden Projections.

Wang H, Li Y, Fan K, Zhao T, Xu K, Zahin M J Epidemiol Glob Health. 2025; 15(1):25.

PMID: 39945980 PMC: 11825438. DOI: 10.1007/s44197-025-00369-y.


Risk of and Mortality After Acute Kidney Injury Following Cancer Treatment: A Cohort Study.

Munch P, Norgaard M, Jensen S, Birn H, Schmidt H, Christiansen C Cancer Med. 2025; 14(3):e70646.

PMID: 39927749 PMC: 11808929. DOI: 10.1002/cam4.70646.


Antimicrobial resistance burden estimates from the bottom-up: research priorities for estimating the impact of antimicrobial resistance in Brazil.

Keenan K, Kiffer C, Carmo E, Silva Correa J, de Abreu A, Massuda A IJID Reg. 2025; 14:100558.

PMID: 39911748 PMC: 11795537. DOI: 10.1016/j.ijregi.2024.100558.


The impact of age, sex, and gender on polypharmacy and potential prescribing cascades: Lessons from five databases.

Rochon P, Li J, OMahony D, Onder G, Petrovic M, Sternberg S J Am Geriatr Soc. 2024; 73(2):520-532.

PMID: 39699297 PMC: 11825996. DOI: 10.1111/jgs.19282.


References
1.
Prentice R, Chlebowski R, Stefanick M, Manson J, Pettinger M, Hendrix S . Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008; 167(10):1207-16. PMC: 2670848. DOI: 10.1093/aje/kwn044. View

2.
Rubin D . The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med. 2006; 26(1):20-36. DOI: 10.1002/sim.2739. View

3.
Rebeiro P, Althoff K, Lau B, Gill J, Abraham A, Horberg M . Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol. 2015; 182(11):952-60. PMC: 4655744. DOI: 10.1093/aje/kwv181. View

4.
Cole S, Stuart E . Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. Am J Epidemiol. 2010; 172(1):107-15. PMC: 2915476. DOI: 10.1093/aje/kwq084. View

5.
Tennant P, Murray E . The Quest for Timely Insights into COVID-19 Should not Come at the Cost of Scientific Rigor. Epidemiology. 2020; 32(1):e2. DOI: 10.1097/EDE.0000000000001258. View